Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Investor focus is likely to be on the impact of the coronavirus outbreak on Sanofi's (SNY) performance when it reports second-quarter results.

Sanofi (SNY) to Report Q2 Earnings: What's in the Cards?

Johnson & Johnson

Pfizer

European efforts to secure potential COVID-19 vaccines from Pfizer , Sanofi and Johnson & Johnson are mired in wrangles over price, payment method and potential liability costs, three EU officials told Reuters.

Exclusive: EU talks with Pfizer, Sanofi, J&J on COVID vaccines hit snags - sources

AbbVie

GlaxoSmithKline

Novartis

As the market continues to deal with the pandemic, these five cheap drug stocks have solid dividend yields of 4% and almost 37% upside.

5 High-Yield Drug Stocks That Are Undervalued With Great Upside

BRIDGEWATER, N.J., July 22, 2020 /PRNewswire/ -- Sanofi Pasteur, the vaccines global business unit of Sanofi, today shipped the first of its influenza vaccine doses to health care providers in the U.S.

Sanofi begins shipping flu vaccines in U.S. for 2020-2021 season

CD38KO NK cell therapy has the potential to maximize the efficacy of anti-CD38 against multiple myeloma

Kiadis announces publication in Blood highlighting proof-of-concept to enhance potency of anti-CD38 antibodies with Kiadis’ K-NK004, recently licensed by Sanofi

   nformation concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)

Sanofi: Information concerning the total number of voting rights and shares - June 2020

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Sanofi (SNY) have what it takes?

Why Sanofi (SNY) is a Great Dividend Stock Right Now

BioNTech SE

Moderna

The European Union is negotiating advance purchase deals of potential COVID-19 vaccines with drugmakers Moderna , Sanofi and Johnson & Johnson as well as biotech firms BioNtech and CureVac, two EU sources told Reuters.

Exclusive: EU in talks with Moderna, BioNtech, CureVac to secure possible COVID vaccines

Quest Diagnostics

Labcorp Holdings Inc

Novavax

Regeneron Pharmaceuticals

COVID-19 crushed the stock market in March. The only real survivors were companies involved with testing, treatments and vaccines.

8 Coronavirus Stocks That Can Deliver Even More Upside Ahead

AstraZeneca

Bristol-Myers

Merck

In a previous article published in GuruFocus, I looked at the top five pharma companies on EvaluatePharma’s list ranked by sales the firms are expected to achieve in 2026.

Pharma Companies Look to Blockbusters to Drive Sales

Sanofi: Buy And Permanently Hold A Value Stock With A Limited Short-Term Downside

CAMBRIDGE, Mass., July 9, 2020 /PRNewswire/ -- Kymera Therapeutics Inc. today announced the company has entered into a multi-program strategic collaboration with Sanofi (NASDAQ: SNY) to develop and commercialize first-in-class protein degrader therapies targeting IRAK4 in patients with...

Kymera Therapeutics And Sanofi Enter Into Strategic Partnership To Advance Novel Protein Degrader Therapies To Patients

iShares Nasdaq Biotechnology ETF

COVID-19 has been the biggest driver of the stock market this year, whether it was the crash in March or recovery that has taken place since then.

5 Speculative COVID-19 Stocks That Could Still Surge

Sanofi (SNY) and Regeneron discontinue U.S.-based phase III coronavirus study on Kevzara following failure to achieve improvement in hospitalized patients with severe COVID-19 patients of statistical significance.

Sanofi/Regeneron's Kevzara Fails in Phase III Coronavirus Study

Gritstone Oncology Inc

For the most part, biotech and pharmaceutical companies are involved in the lengthy process of getting their drug candidates to market through clinical trials.

5 FDA COVID-19 Decisions in July Could Make or Break Stocks

Shares of Regeneron Pharmaceuticals Inc. REGN, +2.18% were down 2.4% and Sanofi's SNY, +0.68% stock declined 1.7% in after-hours trading on Friday after the companies halted a Phase 3 clinical trial testing their rheumatoid arthritis drug Kevzara as a COVID-19 treatment.

Regeneron, Sanofi halt trial for experimental coronavirus drug, shares fall

Inovio Pharmaceuticals

Royalty Pharma

Spain's Pharma Mar is looking at listing on New York's Nasdaq market, joining a flurry of biotech companies aiming to tap investors' voracious appetite for the sector as it tests one of its therapies to treat COVID-19.

Nasdaq's $1.2 trillion biotech index draws Europe's COVID drug hunters

Sanofi (SNY) closed at $51.08 in the latest trading session, marking a +0.33% move from the prior day.

Sanofi (SNY) Gains But Lags Market: What You Should Know

Sanofi (EPA: SAN) said on Friday that it plans on cutting up to 1,680 jobs in a bit to minimise costs and boost profits. The layoff, it added, will only affect its employees in Europe.

Sanofi to layoff up to 1,680 workers in Europe to minimise costs and boost profits

Sanofi said on Friday it is planning to slash up to 1,680 jobs in Europe, confirming what two sources familiar with the matter had previously told Reuters.

Exclusive: Sanofi planning to cut up to 1,680 jobs in Europe

Sanofi SA (SNY) CEO Paul Hudson Hosts R&D Day Investor Event (Transcript)

The company's management is considering a restructuring that may eliminate many positions.

Sanofi's Cost-Cutting Could Mean Big Job Losses

BioMarin Pharmaceutical

Sanofi SA (SNY) has made it clear it wants to get into the rapidly growing gene therapy market, and an acquisition may be the fastest route.

Acquiring Biomarin Would Speed Sanofi Transition to New Therapies

Sanofi is considering cutting hundreds of jobs and will discuss potential steps with staff representatives over the coming days, four sources said on Thursday, the latest move by the French drugmaker's chief executive Paul Hudson to cut costs.

Exclusive: Sanofi considers job cuts as CEO seeks to reduce costs - sources

Telesis Bio Inc

Developing a COVID-19 vaccine in record time will be tough. Producing enough to end the pandemic will be the biggest medical manufacturing feat in history.

News for Sanofi Stock (SNY)